Lung Cancer Diagnostic Test Market by Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others), Imaging Test ( Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy (Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, Others), By Cancer Type (Non-small cell lung cancer and Small Cell Lung Cancer), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others) and By Region - Trends, Analysis and Forecast till 2029

Lung cancer diagnostic test market share is broken down by geography into five segments: Latin America, North America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to hold the top spot in the lung cancer diagnostic and screening market over the forecast period. The market for lung cancer diagnosis and screening in North America is being driven in large part by the growing number of inorganic development strategies, such mergers and acquisitions, employed by the region's top competitors. For instance, leading biopharmaceutical giant AbbVie announced in April 2016 that it had acquired Stemcentrx and its pivotal late-stage medicine, rovalpituzumab tesirine, or Rova-T, which is currently undergoing research in registrational studies for small cell lung cancer (SCLC). A novel biomarker-specific treatment called Rova-T is made from cancer stem cells that focuses on the delta-like protein 3 (DLL3), which is absent from healthy tissue but present in the tumors of nearly 80% of SCLC patients.